Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Maximum tolerated dose (MTD)/Phase 1 part	8 weeks	Toxicity
Primary	Rate of pathological complete remissions (pCR)/Phase 2 part	3 months	Pathohistological response
Secondary	Disease free survival (DFS)	4 years	recurrence and survival
Secondary	Overall survival (OS)	4 years	Survival
Secondary	Loco-regional failure	4 years	Loco-regional recurrence
Secondary	Histopathological R0 resection rate	3 months	Pathohistological response
Secondary	Tumour regression grades	3 months	Pathohistological response
Secondary	Pathological down-staging (ypT0-2N0) rate	3 months	Pathohistological response
Secondary	Neoadjuvant rectal score (NAR)	3 months	Clinical stage and Pathohistological response (\<8 low, 8-16 intermediate, \>16 high risk)
Secondary	Adverse event rate	3 months	Rate of adverse events according to NCI CTC AE v5
Secondary	Rate of perioperative complications	3 months	Perioperative complications

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04177602/registered